

1 **Validating saliva as a biological sample for cost-effective, rapid and routine**
2 **screening for SARS-CoV-2**

3

4 B.R. Ansil^{a*}, Carolin Elizabeth George^b, Sindhulina Chandrasingh^c, Ashwin Viswanathan^d,
5 Mukund Thattai^a, Padinjat Raghu^a, Santhosha Devadiga^e, Arun Geetha Harikumar^e, Pulleri
6 Kandi Harsha^e, Indu Nair^f, Uma Ramakrishnan^{a*}, Satyajit Mayor^a

7

8 ^a National Centre for Biological Sciences, Tata Institute of Fundamental Research,
9 Bangalore, Karnataka, India 560065

10

11 ^b Community Health and Research Division, Bangalore Baptist Hospital, Bangalore,
12 Karnataka, India 560024

13

14 ^c Department of Microbiology, Bangalore Baptist Hospital, Bangalore, Karnataka, India
15 560024

16

17 ^d Nature Conservation Foundation, Mysore, Karnataka, India 570017

18

19 ^e COVID-19 Testing Laboratory, Institute for Stem Cell Science and Regenerative Medicine,
20 Bangalore Life Science Cluster, Bangalore, Karnataka, India 560065

21

22 ^f Department of Medicine and Infectious diseases, Bangalore Baptist Hospital, Bangalore,
23 Karnataka, India 560024

24

25 ***Corresponding author: ansilbr@nchs.res.in (ABR); uramakri@nchs.res.in (UR)**
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 **Abstract**

27 *Purpose:* Compared to nasopharyngeal/oropharyngeal swabs, non-invasive saliva samples
28 have enormous potential for scalability and routine population screening of SARS-CoV-2. In
29 this study, we are investigating the efficacy of saliva samples relative to
30 nasopharyngeal/oropharyngeal swabs for use as a direct source for the RT-PCR based SARS-
31 CoV-2 detection.

32 *Methods:* Paired nasopharyngeal/oropharyngeal swabs and saliva samples were collected
33 from suspected positive SARS-CoV-2 patients and tested using RT-PCR. Generalised linear
34 models were used to investigate factors that explain result agreement. Further, we used
35 simulations to evaluate the effectiveness of saliva-based screening in restricting the spread of
36 infection in a large campus such as an educational institution.

37 *Results:* We observed 75.4% overall result agreement. Prospective positive samples stored for
38 three or more days showed a drastic reduction in the probability of result agreement. We
39 observed 83% result agreement and 74.5% test sensitivity in samples processed and tested
40 within two days of collection. Our simulations suggest that a test with 75% sensitivity, but
41 high daily capacity can be very effective in limiting the size of infection clusters in a
42 workspace. Guided by these results, we successfully implemented a saliva-based screening in
43 the Bangalore Life Sciences Cluster (BLiSC) campus.

44 *Conclusion:* These results suggest that saliva may be a viable sample source for SARS-CoV-
45 2 surveillance if samples are processed immediately. We strongly recommend the
46 implementation of saliva-based screening strategies for large workplaces and in schools, as
47 well as for population-level screening and routine surveillance as we learn to live with the
48 SARS-CoV-2 virus.

49

50 **Keywords:** SalivaDirect, SARS-CoV-2, Non-invasive, Cost-effective, Surveillance

51 **Introduction**

52 The COVID-19 pandemic spread rapidly in India, infecting more than 30 million people in
53 two years [1]. Given this magnitude and speed, COVID-19 presents various diagnostic
54 challenges, in the context of massive population density and limited diagnostic and health
55 infrastructure capabilities. Viral diagnosis has progressed tremendously, and of the various
56 modalities for SARS-CoV-2 diagnosis, the most reliable test is the reverse transcription-
57 polymerase chain reaction (RT-PCR) on Nasopharyngeal/Oropharyngeal swabs collected in
58 Viral Transport Medium (N/OPS-VTM). This demands skilled technical staff, involves
59 procedural complexities such as viral inactivation and RNA extraction. Besides, the sample
60 collection protocol causes significant discomfort to the patient [2] and demands strict
61 protocols for prevention of infection to healthcare workers. These procedural complexities of
62 the test are associated with increased cost and turnaround time.

63
64 The SalivaDirect is an alternative RNA extraction free, cost-effective RT-PCR-based
65 protocol with a short turnaround time and less dependence on the supply chain [3]. Using
66 saliva as a source sample has several advantages: 1) samples can be collected by patients
67 without the help of trained personnel, 2) stringent personal protective equipment (PPE) are
68 not required, 3) non-invasive routine testing is possible 4) dispensing with swabs or VTM
69 adds flexibility, and 5) no requirement for RNA extraction reduces the cost and hence widens
70 its applicability. Evidence related to using saliva for SARS-CoV-2 testing is evolving, and
71 recent studies have reported promising results [4, 5]. Unfortunately, saliva-based tests in
72 India are explored by very few studies [5, 6].

73
74 In this study, we assessed the performance of saliva relative to N/OPS-VTM samples for use
75 as a direct source (without RNA extraction) for the RT-PCR based SARS-CoV-2 detection.

76 We also investigated correlates for discordance between N/OPS-VTM and saliva sample
77 pairs. Further, we used simulations that incorporate concordance to evaluate the effectiveness
78 of SalivaDirect in restricting the infection spread in a large campus such as an educational
79 institution. Finally, we present a case study on the implementation of such a strategy in an
80 educational institution. Through this study, we provide evidence for a low cost, easy, fast,
81 and accurate test that has a considerable advantage in a country like India, especially in
82 learning to ‘live with the virus’.

83

84 **Materials and Methods**

85 *Ethical statement*

86 The study was approved by the Institutional Review Board of Bangalore Baptist Hospital
87 (BBB/IRB/2020/010); Institutional Human Ethics Committee and Institutional Biosafety
88 Committee, National Centre for Biological Sciences (NCBS/IEC-22/01, NCBS/IEC-26/
89 NCBS:34IBSC/UR1).

90

91 *Sample collection, processing and testing for SARS-CoV-2*

92 Samples were obtained from patients of Bangalore Baptist Hospital between December 2020
93 and May 2021. From each individual, a N/OPS-VTM and saliva (5 ml) were collected. Each
94 paired sample was given a unique biorepository number and transported to the COVID-19
95 testing laboratory at Institute for Stem Cell Science and Regenerative Medicine (inStem).
96 Upon arrival, samples were stored in a 4°C refrigerator in the biosafety laboratory. Storage
97 time before processing the samples varied from 0 to 15 days with a mean of 4 days. In case of
98 storage beyond two days, the samples were moved to a -20°C freezer.

99 N/OPS-VTM samples were processed following the Indian Council of Medical Research

100 (ICMR) approved protocol. RNA was extracted using a magnetic bead-based automated Viral

101 RNA Extraction protocol (Beckman Coulter Life Sciences). Saliva were processed following
102 SalivaDirect protocol [3] and tested for RdRP, E and N genes of SARS-CoV-2 and human
103 RNase P gene using NeoDx-CoviDx™ mPlex-4R SARS-CoV-2 RT-PCR Detection kits. Test
104 results were evaluated based on manufacturer's guidelines. Detailed sample collection and
105 testing strategies are provided in the Supplementary material.

106

107 *Analysis*

108 We determined (a) the number of individuals positive for SARS-CoV-2 in both N/OPS-VTM
109 and saliva, (b) those positive only in N/OPS-VTM, (c) those positive only in saliva, and (d)
110 those negative in both N/OPS-VTM and saliva. From this data, we computed the test
111 sensitivity on each sample type. Since nasopharyngeal swab sampling has been shown to
112 produce false negatives by RT-PCR [7], sensitivities for the saliva and the N/OPS-VTM are
113 defined here respectively as $(a+c)/(a+b+c)$ and $(a+b)/(a+b+c)$, considering any individual
114 with a positive result on one or the other sample as true positive [4].

115

116 We compared positive outcomes from the saliva results with true positives and used a
117 Generalized Linear Model (GLM) to understand the factors that explain result agreement (or
118 disagreement). We modelled result agreement/disagreement (success/failure) as a function of
119 the sex of the patient, age, severity of the symptoms (asymptomatic and symptomatic), and
120 storage duration (number of days between collection and testing; grouped into two bins: 0-2
121 days and 3-15 days), assuming a binomial error distribution. This analysis did not include
122 individuals showed inconclusive results. We also assessed the Ct-value distribution of all test
123 genes for concordant samples and compared using Wilcoxon test [8].

124

125 *Modelling infection spread on a network*

126 We explored the effectiveness of campus-wide saliva-based screening using a Monte Carlo
127 simulation of infection transmission in a network of 1600 individuals. In the simulation, a
128 subset of individuals are tested each day, and test results are reported after some delay.
129 Individuals who test positive are isolated, and their contacts are subsequently tested and
130 isolated if positive. We start with a single positive case and run the simulation until there are
131 no infected individuals remaining. The model is stochastic, so each run of the simulation
132 produces a different result. The total number of infections at the end of the simulation defines
133 the size of the cluster. An important goal of mitigation is to limit the size of a cluster seeded
134 by a single infection. The model used for simulation is described in the Supplementary
135 material.

136

137 **Results**

138 *SARS-CoV-2 detection in paired N/OPS-VTM and saliva samples*

139 We observed 75.4% overall result agreement between N/OPS-VTM and saliva sample pairs;
140 30.3% positive agreement and 45.1% negative agreement (Table 1). The inconclusive results
141 were 1.1% and 5.7% for N/OPS-VTM and saliva, respectively. Interestingly, 3.4% of saliva
142 samples were positive when the corresponding N/OPS-VTM were negative. The sensitivity
143 of saliva and N/OPS-VTM were 70.2% and 92.9%, respectively.

144 In the GLM with four variables, duration of storage was independently associated with result
145 agreement (Supplementary Table 1). Among N/OPS-VTM positive or saliva positive
146 patients, we observed a clear drop in result agreement (Fig 1) from 80.8% (SE 70.7-88) to
147 55.5% (SE 45.7-64.9) when samples were stored for more than two days ($p=0.025$).

148 Concordance (83%) and the sensitivity (74.5%) of the saliva test improved when we
149 considered only the samples tested within two days of collection (Table 2). This also resulted
150 in a significant improvement (decrease) in inconclusive test results (1.8% in saliva and 0.9%

151 in N/OPS-VTM). We also found that viral loads were statistically indistinguishable in
152 positive sample pairs for all three viral genes (Wilcoxon $p > 0.05$, Fig 2) among positive
153 concordant samples.

154

155 *Simulations reveal that saliva-based screening can limit infection spread*

156 We track the probability that a single starting infection leads to a large cluster (of size 25 or
157 more) as the testing parameters are varied (Fig 3). This model is not meant to replicate the
158 transmission dynamics of an actual workforce; rather, it is a proof of principle to identify key
159 factors that influence the success of screening. We focus on three key factors of the testing
160 protocol: (a) sensitivity, (b) daily testing capacity, (c) delay in reporting results. In our
161 simulations, in the absence of testing and isolation, the probability of a large cluster is 20%
162 under the assumed parameter values. However, by using a test with 75% sensitivity, at 200
163 tests per day with a one-day delay for results, we decrease the probability of a large cluster
164 ten-fold, to about 2%. Moreover, this protocol works better than a test with 100% sensitivity,
165 but with half the capacity or twice the delay.

166

167 *Implementation of a saliva screening program*

168 In the light of these results, we implemented saliva-based screening in Bangalore Life
169 Science Cluster (BLiSC) campus of ca. 1400 adults. Participants donated a saliva sample
170 once every seven days, and information was collected using a mobile phone application.
171 Individuals were instructed on the sample collection protocol using a video played at the
172 collection centre with no verbal instruction. Samples were tested on the same day, the
173 maximum delay between sample collection and testing being ca. 8 hrs. Over six months, we
174 tested ca. 20000 saliva f samples for SARS-CoV-2 using the protocols described here. An
175 average of 160 samples were tested each day, with a maximum of 300 samples on a single

176 day. Samples were collected between 10 am and 2 pm Monday to Friday, processed in about
177 6 hrs, with final results delivered soon after (the same evening) via mobile phones. Over
178 these six months, we noted only ca. 10 instances where amplification of the internal control
179 (RP) did not occur, presumably due to inhibitory factors in the collected saliva. Over that
180 same period, nine saliva samples tested positive. Of these, eight individuals were completely
181 asymptomatic, and one had very mild generic symptoms suggestive of an upper respiratory
182 tract infection. Among these nine individuals, three tested positive on NP swabs collected on
183 the same day, one tested negative, and the remaining 5 declined further testing and preferred
184 to isolate as per public health guidelines.

185

186 **Discussion**

187 Saliva is emerging as an effective alternative sample type for SARS-CoV-2 testing, with very
188 high sensitivity and specificity [3, 9]. However, N/OPS-VTM remain the more effective
189 sample type for routine diagnosis. Within this context, we examine the efficacy of the saliva
190 for direct RT-PCR and their potential for large-scale testing. Our results suggest that saliva is
191 an excellent alternative to conventional N/OPS-VTM with a reasonable concordance. The
192 overall result agreement between N/OPS-VTM and saliva was 75.4%, slightly lower than
193 reported in recent studies [10, 11]. This reduction in result agreement could be attributed to
194 the longer storage duration of samples, timing of sampling and severity of the disease [12].
195 Since saliva samples were collected without any stabilization media, RNA stability might
196 have been compromised during the storage and freeze-thaw, resulting in lower positivity [13,
197 14]. When recalculated for samples with less than two days of storage, concordance (83%)
198 and sensitivity (74.5%) were closer to those reported in several recent studies [4].

199

200 The sensitivity of saliva was lower than that of N/OPS-VTM. This could be because most
201 samples were follow-up samples of admitted positive patients collected after a week of
202 hospitalisation. Many would have been symptomatic for more than two weeks; however, this
203 information was unavailable. Recent studies have found a higher percentage of viral
204 positivity in saliva when collected within ten days of COVID-19 diagnosis [15, 16]. Delayed
205 sample collection could have been a reason for the low saliva sensitivity in our study.
206 Another important finding of this study is that the Ct value comparison of three viral genes
207 for samples with positive result agreement showed no significant variation. This suggests that
208 these samples would have been taken in the initial phase of the infection. It also indicates that
209 both positive N/OPS-VTM and saliva samples had a similar viral load, suggesting saliva is a
210 valuable alternative sample type for SARS-CoV-2 detection [17].

211
212 Testing of asymptomatic individuals in a workforce is a proactive approach that can help
213 identify and isolate sources of SARS-CoV-2 infection. In choosing the testing protocol, one
214 confronts a trade-off between test sensitivity on the one hand, and testing capacity and testing
215 delay on the other. For example, Rapid Antigen Tests produce immediate results with low
216 sensitivity, while the gold-standard N/OPS RT-PCR test achieves high sensitivity but with
217 limited capacity and delayed results. Furthermore, even a 100% sensitive test cannot prevent
218 spread, since only a fraction of individuals are sampled each day, and individuals in early
219 stages of infection may not test positive. We explored these trade-offs using a simulation of
220 infection transmission. We found that increased testing capacity and decreased delay more
221 than offset decreased test sensitivity, in preventing the emergence of large infection clusters.
222 In particular, higher testing capacity enabled a more rapid cycle for testing an entire
223 workforce, increasing the chance that an infection missed in one cycle was picked up in the
224 next.

225

226 The saliva-based protocol described here meets the criteria highlighted above, for effective
227 workplace screening. It is non-invasive, simple and self-collected without any PPE and can
228 be used directly for RT-PCR [18]. The SalivaDirect protocol does not require RNA
229 extraction, a significant bottleneck in the testing workflow [3]. These unique features of
230 saliva screening significantly reduce testing costs and complexity when compared to N/OPS-
231 VTM testing although we have not performed a formal cost analysis. Adopting saliva-based
232 screening could yield higher testing capacity and shorter delays in result reporting. In case of
233 resource constraints, saliva pooling can also be employed to further reduce overall turnaround
234 time and test burden [19, 20]. Given these benefits, as well as the observed concordance
235 between N/OPS-VTM and saliva, we piloted saliva-based screening to detect COVID-19
236 infections in the BLiSC academic campus. We found that this screening and surveillance
237 effort was successful, enabling the campus to remain functional during the ongoing COVID-
238 19 pandemic in India. Regular screening, which depends heavily on participant compliance,
239 allows the resumption of normal workplace activity with enhanced safety with respect to
240 COVID-19 infection. The approach described here can be scaled up for routine surveillance
241 efforts, and implemented in schools, offices, academic institutions, and residential
242 apartments.

243

244 **Conclusion**

245 While there is substantial evidence for saliva as a source sample for SARS-CoV-2 detection
246 globally, we present here a comprehensive study where we validate saliva as a screening tool
247 for SARS-CoV-2 in India. Simulations aimed at detecting infection clusters guided the setup
248 of a regular saliva-based screening on an academic campus, given estimates of concordance
249 between saliva and nasopharyngeal/oropharyngeal swabs. Finally, we highlight the successful

250 implementation of such a strategy on an academic campus. We hope this study can serve as
251 an example and provide guidelines for the setup of a rapid and efficient approach to safe
252 functioning of large establishments, including schools and industries, in the coming years as
253 the world continues to live through a pandemic.

254

255 **Acknowledgements**

256 This work was primarily supported by NCBS/TIFR core fund, and we acknowledge the
257 support of the Department of Atomic Energy (DAE), Government of India, under Project
258 Identification No. RTI 4006; and philanthropic support from the Azim Premji Foundation.

259 We acknowledge the CCAMP-InDx program for facilitating the saliva collection receptacle
260 and transport medium from Kriyamed (<https://www.kriyamed.com/>) for campus screening.

261 We are grateful to COVID-19 testing laboratory staff for helping with sample processing and
262 RT-PCR testing; Mr. Prem Chandra Gautam, technical and research services teams at NCBS
263 for their assistance in implementing campus saliva testing. We thank Prof. Apurva Sarin and
264 Prof. Colin Jamora for facilitating the project. ABR is supported by the SPM research
265 fellowship by CSIR-HRDG. UR is a Senior fellow DBT-Wellcome Trust India Alliance
266 (IA/S/16/2/502714). SM is a JC Bose Fellow of the Department of Science and Technology,
267 Government of India, and a Margadarshi Fellow of the DBT-Wellcome Trust India Alliance
268 (IA/M/15/1/502018).

269

270 **CRedit author statement**

271 **B.R. Ansil:** Conceptualization, Data curation, Analysis, Writing - Original Draft, Writing -
272 Review and Editing. **Carolyn Elizabeth George:** Conceptualization, Data curation, Analysis,
273 Writing - Original Draft, Writing - Review and Editing. **Sindhulina Chandrasingh:**
274 Conceptualization, Data curation, Writing - Original Draft, Writing - Review and Editing.

275 **Ashwin Viswanathan:** Conceptualization, Analysis, Writing - Original Draft, Writing -
276 Review and Editing. **Mukund Thattai:** Conceptualization, Methodology, Analysis, Writing -
277 Original Draft, Writing - Review and Editing. **Padinjat Raghu:** Conceptualization,
278 Methodology, Writing - Original Draft, Writing - Review and Editing. **Santhosha Devadiga:**
279 Investigation, Data curation. **Arun Geetha Harikumar:** Investigation, Data curation,
280 Writing - Review and Editing. **Pulleri Kandi Harsha:** Investigation, Data curation. **Indu**
281 **Nair:** Conceptualization, Data curation. **Uma Ramakrishnan:** Conceptualization, Writing -
282 Original Draft, Writing - Review and Editing, Supervision. **Satyajit Mayor:**
283 Conceptualization, Writing - Review and Editing and Supervision.
284
285 **Conflict of Interest**
286 The authors declare that they have no conflict of interest.

287 **References**

- 288 1. <https://www.mohfw.gov.in> (2021) Ministry of Health and Family Welfare, Government
289 of India. Accessed 10 Dec 2021
- 290 2. Wang H, Liu Q, Hu J, et al (2020) Nasopharyngeal Swabs Are More Sensitive Than
291 Oropharyngeal Swabs for COVID-19 Diagnosis and Monitoring the SARS-CoV-2
292 Load. *Front Med* 7:334. <https://doi.org/10.3389/fmed.2020.00334>
- 293 3. Vogels CBF, Watkins AE, Harden CA, et al (2021) SalivaDirect: A simplified and
294 flexible platform to enhance SARS-CoV-2 testing capacity. *Med* 2:263-280.e6.
295 <https://doi.org/10.1016/j.medj.2020.12.010>
- 296 4. Ibrahim N, Delaunay-Moisan A, Hill C, et al (2021) Screening for SARS-CoV-2 by
297 RT-PCR: Saliva or nasopharyngeal swab? Rapid review and meta-analysis. *PLOS ONE*
298 16:e0253007. <https://doi.org/10.1371/journal.pone.0253007>
- 299 5. Azmi I, Faizan MI, Kumar R, et al (2021) A Saliva-Based RNA Extraction-Free
300 Workflow Integrated With Cas13a for SARS-CoV-2 Detection. *Front Cell Infect*
301 *Microbiol* 11:632646. <https://doi.org/10.3389/fcimb.2021.632646>
- 302 6. Bhattacharya D, Parai D, Rout UK, et al (2021) Saliva for diagnosis of SARS-CoV-2:
303 First report from India. *J Med Virol* 93:2529–2533. <https://doi.org/10.1002/jmv.26719>
- 304 7. Woloshin S, Patel N, Kesselheim AS (2020) False Negative Tests for SARS-CoV-2
305 Infection — Challenges and Implications. *N Engl J Med* 383:e38.
306 <https://doi.org/10.1056/NEJMp2015897>
- 307 8. Wilcoxon F (1945) Individual Comparisons by Ranking Methods. *Biom Bull* 1:80.
308 <https://doi.org/10.2307/3001968>

- 309 9. Butler-Laporte G, Lawandi A, Schiller I, et al (2021) Comparison of Saliva and
310 Nasopharyngeal Swab Nucleic Acid Amplification Testing for Detection of SARS-
311 CoV-2: A Systematic Review and Meta-analysis. *JAMA Intern Med* 181:353.
312 <https://doi.org/10.1001/jamainternmed.2020.8876>
- 313 10. Landry ML, Criscuolo J, Peaper DR (2020) Challenges in use of saliva for detection of
314 SARS CoV-2 RNA in symptomatic outpatients. *J Clin Virol* 130:104567.
315 <https://doi.org/10.1016/j.jcv.2020.104567>
- 316 11. Vaz SN, Santana DS de, Netto EM, et al (2020) Saliva is a reliable, non-invasive
317 specimen for SARS-CoV-2 detection. *Braz J Infect Dis* 24:422–427.
318 <https://doi.org/10.1016/j.bjid.2020.08.001>
- 319 12. Iwasaki S, Fujisawa S, Nakakubo S, et al (2020) Comparison of SARS-CoV-2 detection
320 in nasopharyngeal swab and saliva. *J Infect* 81:e145–e147.
321 <https://doi.org/10.1016/j.jinf.2020.05.071>
- 322 13. Matic N, Stefanovic A, Leung V, et al (2021) Practical challenges to the clinical
323 implementation of saliva for SARS-CoV-2 detection. *Eur J Clin Microbiol Infect Dis*
324 40:447–450. <https://doi.org/10.1007/s10096-020-04090-5>
- 325 14. Pasomsub E, Watcharananan SP, Watthanachockchai T, et al (2021) Saliva sample
326 pooling for the detection of SARS-CoV-2. *J Med Virol* 93:1506–1511.
327 <https://doi.org/10.1002/jmv.26460>
- 328 15. Wyllie AL, Fournier J, Casanovas-Massana A, et al (2020) Saliva or Nasopharyngeal
329 Swab Specimens for Detection of SARS-CoV-2. *N Engl J Med* 383:1283–1286.
330 <https://doi.org/10.1056/NEJMc2016359>

- 331 16. Uwamino Y, Nagata M, Aoki W, et al (2021) Accuracy and stability of saliva as a
332 sample for reverse transcription PCR detection of SARS-CoV-2. *J Clin Pathol* 74:67–
333 68. <https://doi.org/10.1136/jclinpath-2020-206972>
- 334 17. Yokota I, Hattori T, Shane PY, et al (2021) Equivalent SARS-CoV-2 viral loads by PCR
335 between nasopharyngeal swab and saliva in symptomatic patients. *Sci Rep* 11:4500.
336 <https://doi.org/10.1038/s41598-021-84059-2>
- 337 18. Medeiros da Silva RC, Nogueira Marinho LC, de Araújo Silva DN, et al (2020) Saliva
338 as a possible tool for the SARS-CoV-2 detection: A review. *Travel Med Infect Dis*
339 38:101920. <https://doi.org/10.1016/j.tmaid.2020.101920>
- 340 19. Perchetti GA, Sullivan K-W, Pepper G, et al (2020) Pooling of SARS-CoV-2 samples to
341 increase molecular testing throughput. *J Clin Virol* 131:104570.
342 <https://doi.org/10.1016/j.jcv.2020.104570>
- 343 20. Watkins AE, Fenichel EP, Weinberger DM, et al (2020) Pooling saliva to increase
344 SARS-CoV-2 testing capacity. *Infectious Diseases (except HIV/AIDS)*
345

346 **Tables and Figures**

347

348 **Table 1:** A matrix showing the alignment of results from the two methods - N/OPS-VTM

349 and Saliva - for all samples (N = 175). The asterisk indicate result agreements.

N/OPS-VTM (N=175)					
		Positive	Negative	Inconclusive	Total
Saliva (N=175)	Positive	30.3% (53)*	3.4% (6)	0.6% (1)	34.3% (60)
	Negative	14.3% (25)	45.1% (79)*	0.6% (1)	60.0% (105)
	Inconclusive	5.7% (10)	0.0% (0)	0.0% (0)	5.7% (10)
	Total	50.3% (88)	48.6% (85)	1.1% (2)	175

350

351


352 **Table 2:** A matrix showing the alignment of results from the two methods - N/OPS-VTM

353 and Saliva - for samples tested within two days of collection (N = 112). The asterisk indicate

354 result agreements.

N/OPS-VTM (N=112)					
		Positive	Negative	Inconclusive	Total
Saliva (N=112)	Positive	27.7% (31)*	3.6% (4)	0.9% (1)	32.1% (36)
	Negative	10.7% (12)	55.4% (62)*	0.9% (1)	67.0% (75)
	Inconclusive	0.9% (1)	0.0% (0)	0.0% (0)	0.9% (1)
	Total	39.3% (44)	59.0% (66)	1.8% (2)	112


355



356

357 **Fig 1:** Probability of result agreement in positive samples (0-2 days: N = 49; 3-15 days: N =
358 46). Samples stored for more than two days showed high result disagreement between paired
359 samples. Error bars are standard errors and the asterisk denotes a significant difference.


360



361

362 **Fig 2:** Boxplot showing Ct value distribution for three SARS-CoV-2 genes and human
363 RNase P gene. There is no significant difference in mean Ct values for viral genes between
364 N/OPS-VTM and saliva samples.

365



366

367 **Fig 3:** Results of a Monte Carlo simulation of infection transmission on a network of 1600
368 individuals. We track the probability that a single starting infection seeds a cluster of 25 or
369 more infections. We compare a baseline protocol that has a capacity of 200 tests per day and
370 a delay in reporting of one day (green), with variations having higher or lower capacities or
371 delays (see legend). Error bars represent SEM values over 5000 replicate simulations.

372